Five things for pharma marketers to know: Tuesday, June 30

Five things for pharma marketers to know: Tuesday, June 30

Vertex's cystic-fibrosis drug approval likely to come this week; Roche's multiple-sclerosis treatment hits primary and secondary endpoints; Regeneron/Sanofi debut film about high cholesterol

Manufacturers pay $6.5 billion to healthcare providers in 2014

Manufacturers pay $6.5 billion to healthcare providers in 2014

The government released new data showing how much pharma and device companies spent for research and marketing purposes last year.

Havas Health acquires London-based PR shop

Havas Health acquires London-based PR shop

Havas Health adds PR agency Just:: Health Communications in bid to expand its global footprint.

Five things for pharma marketers to know: Monday, June 29

Five things for pharma marketers to know: Monday, June 29

A new Novartis drug shows promise; Samsung Group is poised to move on its next major growth sector; Valeant Pharmaceuticals is on the hunt again

Five things for pharma marketers to know: Friday, June 26

Five things for pharma marketers to know: Friday, June 26

Supreme Court affirmed the legality of the Affordable Care Act for a second time on Thursday

You Have 100 Days To Make An Impact. What Are You Waiting For?

You Have 100 Days To Make An Impact. What Are You Waiting For?

Just landed a new job? You've got 100 days to make an impression. Here are some suggestions.

Myelin acquires agencies in Chicago and Atlanta

Myelin acquires agencies in Chicago and Atlanta

Fourth and fifth members of network add healthcare advertising and PR expertise.

Five things for pharma marketers to know: Wednesday, June 24

Five things for pharma marketers to know: Wednesday, June 24

AbbVie says curative effects hold whether Viekira Pak used with or without ribavirin; House Republicans vote to eliminate IPAB; analyst sets high price target for Alexion.

Treato bolsters social-media insight

The consumer-insights firm said it's debuting a listening feature that will make it harder for pharma to ignore Twitter, Reddit and the other big social platforms.

BMS combo would gain heft in melanoma space, say analysts

BMS combo would gain heft in melanoma space, say analysts

The promise of an Opdivo/Yervoy combination, now awaiting FDA approval, has more to do with payer strategy than efficacy, analysts say.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.